Market Overview

Genprex to Present at NobleConXV in Fort Lauderdale, Florida

Share:

Noble Capital Markets' Fifteenth Annual Investor / Equity Conference

Genprex, Inc. (NASDAQ:GNPX), a clinical-stage gene therapy company
developing a new approach to treating cancer based upon a novel
proprietary technology platform, today announced that its President and
Chief Operating Officer, Julien Pham, MD, MPH, will deliver a
presentation about the company's unique, leading-edge gene therapies and
will also participate in a discussion panel on the topic of "Novel
Therapies at the Cutting Edge of Cancer Research" at NobleConXV - Noble
Capital Markets' Fifteenth Annual Investor Conference at the W Hotel in
Fort Lauderdale, Florida.

Genprex's NobleConXV Presentation:
Presentation – The
Genprex Platform: A Novel Approach to Cancer Treatment
Date:
Monday, January 28, 2019
Time: 2 p.m. (EST)
Room:
Studio 1
Venue: W Hotel, 401 N Fort Lauderdale Beach Blvd,
Fort Lauderdale, FL 33304

Genprex's NobleConXV Panel Discussion:
Panel Presentation
- Novel Therapies at the Cutting Edge of Cancer Research
Date:
Monday, January 28, 2019
Time: 5:30 p.m. (EST)
Room:
Studio 3
Venue: W Hotel, 401 N Fort Lauderdale Beach Blvd,
Fort Lauderdale, FL 33304

"We are honored to deliver a presentation about our cutting-edge
technologies that have the potential to change the way cancer patients
are treated," said Rodney Varner, Genprex's Chief Executive Officer and
Chairman. "NobleCon is the perfect place to showcase the science behind
this innovative approach to gene therapy."

Genprex's approach to treating cancer is based on a proprietary
technology platform that includes the company's initial product
candidate, Oncoprex™ immunogene therapy. Oncoprex's multimodal mechanism
of action has demonstrated the ability to interrupt cell-signaling
pathways that cause replication and proliferation of cancer cells, while
re-establishing pathways for apoptosis, or programmed cell death, in
cancer cells. Oncoprex has also been shown to block mechanisms that
create drug resistance. The company holds a portfolio of 30 issued
patents and two pending patents covering its platform technologies.

Genprex is looking forward to presenting to the conference and will have
a high-definition webcast of the presentation available the following
day on the company's website at www.genprex.com.
It will also be available as part of a complete catalog of presentations
available at Noble Capital Markets' Conference website at www.nobleconference.com
as well as the new investor portal created by Noble called Channelchek
at www.channelchek.com.
The webcast will be archived on the company's website, the NobleCon
website and on Channelchek.com for 90 days following the event.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing
potentially life-changing technologies for cancer patients, based upon a
unique proprietary technology platform, including Genprex's initial
product candidate, Oncoprex™ immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex's platform technologies are designed to
administer cancer fighting genes by encapsulating them into nanoscale
hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins
that are missing or found in low quantities. Oncoprex has a multimodal
mechanism of action whereby it interrupts cell signaling pathways that
cause replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells, and
modulates the immune response against cancer cells. Oncoprex has also
been shown to block mechanisms that create drug resistance. Visit the
company's web site at genprex.com
or follow Genprex on Facebook,
Twitter
and LinkedIn.

About Noble Capital Markets, Inc.

2019 marks Noble Capital Markets' 35th anniversary. The Company is an
equity-research driven, full-service, investment & merchant banking
boutique focused on emerging growth companies. In addition to NobleCon,
Noble hosts numerous "non-deal" corporate road shows across the United
States and Canada. In late 2018, Noble launched Channelchek.com which
features advanced market data, institutional-quality research, balanced
news, videos and podcasts covering more than 6,000 emerging growth
companies. There is no cost for investors to join. Members: FINRA, SIPC,
MSRB. www.noblecapitalmarkets.com

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effects of Oncoprex or TUSC2 on cancer, and
statements regarding the synergies obtained by combining Oncoprex with
EGFR inhibitors and checkpoint inhibitors. Risks that contribute to the
uncertain nature of the forward-looking statements include the presence
and level of TUSC2's effect on cancer, as well as the timing and success
of our clinical trials and planned clinical trials of TUSC2 and Oncoprex
and our other potential product candidates and the timing and success of
obtaining FDA approval of Oncoprex and our other potential product
candidates. These and other risks and uncertainties are described more
fully under the caption "Risk Factors" and elsewhere in our filings and
reports with the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak only as
of the date on which they were made. We undertake no obligation to
update such statements to reflect events that occur or circumstances
that exist after the date on which they were made.

View Comments and Join the Discussion!